Hormone Evaluation in Artificial Reproductive Technology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

810 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2024-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation.

Outcome will be measured as pregnancy success, live born babies and unwanted side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

NCT01353846

Infertility

UNKNOWN PHASE4

Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

NCT01339299

Controlled Ovarian Stimulation Infertility

COMPLETED PHASE4

Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol

NCT03693534

Pregnancy, Ovarian

UNKNOWN

Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients

NCT01206803

Infertility, Subfertility

COMPLETED

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

NCT01735422

Infertility

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Women undergoing in vitro fertilization receive high doses of the gonadotropins follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG), which is acting as luteinizing hormone (LH) for stimulation of the ovaries in order to obtain a high number of eggs. There are however marked individual differences in the hormonal response, ranging from lack of increased egg maturation to hyper stimulation. The hypothesis is that genetic variants in the gonadotropin receptors (LH and FSH receptors), are influencing the outcome. This assumption is supported by a recent study on more than 600 women undergoing in vitro fertilization, demonstrating that whereas only 10% of women with asparagine in both genes (FSHR N680S and LHR N312S) became pregnant, 40% of those with serine did (Lindgren I et al. Hum Repr 2016; 3:672-83).

Most (90%) of the women were treated with rFSH (recombinant). However, of the 10% asparagine carriers who actually became pregnant, most if not all, were treated with menotropin - a urine derivated compound (Menopur, Ferring), which contains both LH and FSH. This finding was not stressed in the manuscript as it could have been due to chance because of the small number of women treated with menotropin.

The objective is therefore to perform a prospective randomized study regarding efficacy of treatment in the first and second in vitro fertilization trial with rFSH and menotropin, respectively, genotype taken into account.

In total 890 women, 445 in Poznan, Poland and 445 in Malmö, Sweden, with unexplained infertility or a male or tubal factor indication for treatment will be invited to participate in the study. At first appointment, information is provided and informed consent retrieved. Two blood samples are drawn and stored at -20°C; one for subsequent genotyping and one for anti mullerian hormone measurement. The succeeding treatment is according to normal procedures at respective clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Women undergoing in vitro fertilization are allocated to either menotropin (urin derivate) or recombinant follicle stimulating hormone.

Inclusion criteria are:

* younger than 40 years of age
* more than 12 months of unprotected intercourse
* normal ovulatory cycles 26-32 days
* first or second IVF treatment
* indication for IVF is male factor
* tubal factor or unexplained infertility.

Exclusion criteria are:

* Anti müllerian hormone less than 5pmol or FSH more than 12 cycle day 2-3
* Endometriosis
* polycystic ovarian syndrome
* pre ovarian failure
* smoking
* male age more than 56.

The succeeding treatment is according to normal procedures at respective clinic.

End points are: total hormonal dosage, number of retrieved oocytes, fertilization rate, rate of blastocyst transfer, pregnancy rate, live birth rate.

Adverse effects e.g overstimulation is recorded.

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Patients and care providers need to know the type of hormone provided in order to be able to instruct and treat the patient. However, all roles are masked regarding the genotype.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Follitropin alpha

Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.

Group Type ACTIVE_COMPARATOR